Elevated Klotho promoter methylation is associated with severity of chronic kidney disease.
Klotho (KL) expression is down-regulated in the renal tissues of chronic kidney disease (CKD) animal models and patients with end-stage renal disease. The putative role of KL promoter hypermethylation in the progression of CKD remains unclear. The present study aimed to determine renal and peripheral blood mononuclear cells (PBMC) levels of KL promoter methylation and analyze their relationship with clinical and histological severity in patients with CKD. Using bisulfite pyrosequencing, renal and PBMC levels of KL promoter methylation were quantified in 47 patients with CKD. 47 nephrectomy specimens of patients with renal cell carcinoma and 48 PBMC specimens of healthy volunteers were used as renal tissue and PBMC controls, respectively. Renal expression of KL protein was assayed by immunohistochemistry staining. Receiver operating characteristic (ROC) curve was used to identify the optimal cut-off value of PBMC KL promoter methylation level for renal KL promoter hypermethylation. Higher levels of KL promoter methylation were observed in renal tissue and PBMC in patients with CKD compared with controls (8.79±3.24 vs. 5.17±1.11%, P<0.001; 7.20±2.79 vs. 3.27±0.79%, P<0.001). In these patients, renal KL methylation level correlated inversely with renal KL immunostaining intensity (ρ=-0.794, P<0.001). Estimated glomerular filtration rate correlated inversely with renal and PBMC levels of KL promoter methylation (r=-0.829, P<0.001; r=-0.645, P<0.001), while tubulointerstistial fibrosis score correlated positively (ρ=0.826, P<0.001; ρ=0.755, P<0.001). PBMC KL promoter methylation level correlated positively with renal KL promoter methylation level in patients with CKD (r=0.787, P<0.001). In ROC curve, the area under curve was 0.964 (P<0.001) and the optimal cut-off value was 5.83% with a sensitivity of 93.8% and specificity of 86.7% to predict renal KL promoter hypermethylation. The degree of KL promoter methylation is associated with clinical and histological severity of CKD. PBMC KL promoter methylation level may act as a potential biomarker of renal KL promoter hypermethylation.
Laboratory of Kidney Disease, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Jing
J
Chen
Xiaoyan
X
Zhang
Han
H
Zhang
Jing
J
Lin
Chen
C
Zhang
Qing
Q
Wu
Xiaoqiang
X
Ding
D000328:Adult; D000368:Aged; D019175:DNA Methylation; D005260:Female; D005919:Glomerular Filtration Rate / Q000502:physiology; D005966:Glucuronidase / Q000235:genetics*; D006801:Humans; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D000090265:Klotho Proteins; D008297:Male; D008875:Middle Aged; D011401:Promoter Regions, Genetic / Q000235:genetics*; D051436:Renal Insufficiency, Chronic / Q000235:genetics* / Q000473:pathology*; D055815:Young Adult
D005966:Glucuronidase; D000090265:Klotho Proteins